I too doubt the sources for your information. My facts come from the USPTO, clinicaltrials.gov etc. I do not rely on company propaganda or other message board posts or opinions. You have yet to prove that I am wrong when I posted that there are multiple issued and pending patents in this field, that there are approximately 20 clinical studies underway or recently completed with directly competitive products, that the company is in default of their loan and a demand has been issued, that the company has seriously negative working capital, that the company has indicated that its internal controls are inadequate. Those are all facts and spinning does not make those facts go away. Objective investors know not to go off on tangents, such as the prosecution of patent applications when there already are patents issued or pending in the field. Objective investors are not easily swayed by the perceived enthusiasm of management on conference calls, all one experienced in teh field has to do is look back at HEB, CTIC etc to name a few recent examples of management painting a very rosy picture.
News 
Market Data 
Discover 
AI
